Cemsidomide (CFT7455)

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
224 patients (estimated)
Sponsors
C4 Therapeutics, Inc.
Tags
IKZF1/3
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1124
NCT Identifier
NCT04756726

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.